\
&
Contact us
\
&
Contact us
This was 1 year ago
Locationvirtual
ProgrammesThe ERC Executive Agency organizes a second webinar for applicants to the ERC Advanced Grant 2024 call (call deadline 29 August 2022):
Are you preparing your application to the ERC Advanced Grant 2024 call to be submitted before the 29 August deadline? Assisting a Principal Investigator in their proposal preparation? Having doubts about how to fill in the new lump sum budget forms? Any other problem? This webinar is for you.
On the final stretch of the Advanced Grant 2024 application period, our call coordinators and lump sums experts will guide you over the submission process and answer your practical questions online.
Useful links and documents
Before the webinar, you may find useful to check the official information, the answers to most of the questions that applicants have asked us so far, and our previous webinar focused on lump sums.
For more personalised help, you can always send your question to ERC-2024-ADG-APPLICANTS@ec.europa.eu
For this webinar no registration is needed. All information related to this webinar and the Webex connection details can be found in this announcement on the ERC website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
